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Abstract: 
 
Acute Myeloid Leukemia (AML) is a malignant disease associated with poor outcomes.            
One of the major clinical challenges is suffering relapse after achieving a complete             
remission. Leukemic Stem Cells (LSC) persist in the minimal residual disease cell            
populations and cause AML relapse because they are assumed to be more resistant to              
standard chemotherapy. Therefore, these cells must be specifically targeted in AML           
patients. Long non-coding RNAs (lncRNA) are distinguished by having more than 200            
nucleotides and regulate cellular function. Their role in LSCs is yet to be determined. 
We analyzed 377 AML patients for levels of expression of various lncRNAs. Gene             
expression signatures (GES) from AML LSC populations have been defined and           
expression of a ‘core enriched’ (CE) GES, representing 44 genes deregulated in LSCs,             
is correlated with lower survival rates. We studied associations between the CE-GES            
and lncRNA expression profiles and identified 161 lncRNAs that were found to be             
deregulated in the AML patients. Of these, 152 lncRNAs were found to be higher              
expressed in high CE than low CE patients, indicating that they present in AML patient’s               
gene expression profiles that have more characteristics of stem cells. Among these            
lncRNAs, ​DANCR​ was found in patients with high CE score. 
To examine effects of ​DANCR in LSCs, we performed a long-term culture initiating cell              
(LTC-IC) assay which quantified the frequency of stem cells in a given population. Cells              
were treated with transferrin-conjugated anionic lipopolyplex nanoparticle       
(transferin-NP-siDANCR or transferin-NP-siSCR controls) which work as a delivery         
4 
method for treatment. We found significantly fewer amount of stem cells were present in              
the DANCR knockdown population compared to scramble controls.  
Next, Real Time PCR (qRT-PCR) was performed to compare ​DANCR ​expression in            
AML patients’ bone marrow to healthy bone marrow. The amount of ​DANCR ​expression             
varied between patients but was significantly elevated compared to the control bone            
marrow (p<0.01). Specifically, in LSC enriched populations (n=4), ​DANCR expression          
was significantly higher within individual patients (n=4). To determine the role of ​DANCR             
in LSC self-renewal, a colony forming unit (CFU) was performed with ​DANCR            
knockdown in CD34+ AML patients (n=3). Nanoparticle was used in CD34+ enriched            
AML cells to perform the CFU. After replating, we found significantly fewer colonies in              
DANCR knockdown cells when compared to a scramble control (p=0.03, average           
decrease: 38.9%). A celltrace violet (CTV) assay was performed to assess quiescence            
of primary AML blast cells after ​DANCR knockdown. A significant decrease in the             
number of quiescent (i.e. CTV max/CD34+) cells were found in the ​DANCR knockdown             
group compared to scramble controls (p<0.05). Finally, ​in vivo experiments were           
performed by conditioning mice with radiation followed by treatment of          
Tf-NP-anti-​DANCR​. This caused a significant decrease in engraftment of mice          
compared to scramble control (p<0.001) 
Our data show that the lncRNA, ​DANCR, ​is overexpressed in LSCs. Our experiments             
suggest that ​DANCR ​may play a functional role in AML.  
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Section 1: Introductions 
 
Acute Myeloid Leukemia 
 
Acute myeloid leukemia (AML) is a malignant disease that is highly heterogeneous with             
respect to genetic abnormalities and outcome. In approximately 20% of newly           
diagnosed patients, initial chemotherapy fails and about 65% of patients who achieve a             
complete remission, relapse during their lifetime. Although there have been many           
advances in understanding of AML, long-term survival rates are low.​1-3  
AML is characterized by immature, abnormally proliferating myeloid cells. Cell          
subpopulations of the disease include bulk blast cells, the majority of cells, and rare              
leukemic stem cells (LSC) that are relatively quiescent.  
Leukemic Stem Cells 
 
Alexey Bersenev: Cell Trials 2007 
 
The LSC model postulates that AML consists of heterogeneous cell populations. The            
LSC subpopulation is essential for leukemia maintenance and therefore can be a            
potential pharmacological target for eradication. 
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A potential cause of relapse is the persistence of LSCs and their quiescent nature.​4-9              
This quiescence also makes them less sensitive to standard chemotherapy, which           
targets mainly rapidly dividing cells.​10-12 A better understanding of the effects of LSCs             
might lead to the development of novel therapies that prevent relapse and improve             
outcome by eliminating LSCs.​6, 13-14  
Long non-coding RNAs 
Long non-coding RNAs (lncRNAs) have a transcript length of 200 nucleotides or longer             
and are located within overlapping antisense transcripts or intergenic stretches of           
protein coding genes. LncRNAs make up a heterogeneous group of transcripts that            
regulate cellular functions necessary for cell survival including imprinting, cell cycle,           
epigenetic regulation and apoptosis, however, they have no protein coding potential.​15-17           
One role of lncRNAs is to remodel and loop chromatin in cancer cells while also               
facilitating cross talk between different mechanisms.​16 The role of lncRNA is yet to be              
determined in LSCs. 
Core Enriched Gene Expression Signature and ​DANCR 
A ‘core enriched’ gene expression signature (CE-GES), created by Eppert et al,            
uses a formula to correlate LSC gene signatures with patient clinical outcomes.​4 GES             
from AML LSC populations have been defined and expression of a CE-GES,            
representing 44 genes deregulated in LSCs, is correlated with lower survival rates. We             
studied associations between the CE-GES and lncRNA expression profiles and          
identified 161 lncRNAs that were found to be deregulated in the AML patients. Of these,               
152 lncRNAs were found to be higher expressed in high CE than low CE patients,               
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indicating that they present in AML patient’s gene expression profiles that have more             
characteristics of stem cells. Among these lncRNAs, ​DANCR was found in patients with             
high CE score. 
DANCR was also chosen among the top deregulated RNAs due its conservation            
between humans and mice, and its characterization as an intergenic lncRNA. These            
conditions are optimal for experimentation and translation of results. 
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Section 2: Project Description 
Aims 
● Identification of a lncRNA signature that is associated with LSCs. 
● Elucidation of the role of the lncRNA ​DANCR​ in LSCs. 
Project Summary 
AML is a clonal, neoplastic disease that is heterogeneous at the molecular, cytogenetic,             
cellular and clinical level. While advances have been made towards understanding the            
biology and pathogenesis of AML, the prognosis for AML patients is still poor.​1 Our view               
of a morphologically homogeneous and functionally static blast population present in the            
bone marrow (BM) and blood of AML patients has now evolved into our current              
perspective of multiple dynamic and heterogeneous cell subpopulations. These cells          
include the relatively rare leukemia stem cells (LSCs). LSCs have acquired abnormal            
self-renewal and partial maturation ability, are considered responsible for disease          
initiation and maintenance and are more quiescent, making them more resistant to            
standard chemotherapies, leading to relapse.​4,12,15 Therefore, targeting LSCs may         
represent an essential step for complete eradication of the disease. 
LncRNAs are 200 nucleotides or longer in intergenic stretches or overlapping gene            
coding sequences. They have cellular functions including gene regulation and          
imprinting, however, they are not translated into proteins.​16 Their role in LSCs has yet to               
be determined. 
To identify a lncRNA specific in LSCs, we analyzed BM samples (n=377) of             
cytogenetically normal AML (CN-AML) for a core enriched gene expression signature.           
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We correlated these data with lncRNA profiles from whole transcriptome sequencing           
(RNA-seq). We found 161 lncRNAs to be deregulated in AML patients. One of the top               
upregulated lncRNAs, ​DANCR, was previously discussed in publications on HCC which           
was found to promote ‘stemness’ by interacting with β-catenin and the WNT pathway.​17 
Our projection is to continue to define a role of ​DANCR in LSCs by determining its role                 
in AML patients. 
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Section 3: Methods and Results 
Core Enriched, Gene Expression Signature Analysis 
To identify lncRNAs that may play a functional role in LSCs, we analyzed 365 younger               
(<60 years old) and 76 older (≥60 years old) adult cytogenetically normal AML             
(CN-AML) patients to derive a LSC-specific lncRNA signature.​4 This analysis compares           
gene expression signatures associated with LSCs and HSCs.​7 We studied associations           
between the CE-GES and lncRNA expression profiles and identified 161 lncRNAs that            
were found to be deregulated in the AML patients. Of these, 152 lncRNAs were found to                
be higher expressed in high CE than low CE patients, indicating that they present in               
AML patient’s gene expression profiles that have more characteristics of stem cells.            
Among these lncRNAs, ​DANCR was found in patients with high CE score. (Figure 1).              
Because lncRNAs are a group of heterogeneous RNAs and are comprised of multiple             
different RNA classes, we further classified the lncRNAs using the GENCODE v22            
database. It has been shown that the most common were long intergenic non-coding             
RNAs (lincRNAs; 30%), antisense RNAs (19%) and sense intronic RNAs (13%).​19           
Looking at individual lncRNAs, ​DANCR was among the top deregulated lncRNAs in            
both, younger and older, CN-AML patients with CE​High ​score. We chose to analyze the              
potential regulatory role of ​DANCR further because to it was previously described to             
play an important role in de-differentiation of epidermal progenitor cells and malignant            
transformation of various tissues.​17, 20-22 Additionally, ​DANCR has been shown to           
regulate the WNT pathway, which is an essential for stem cell function. Finally, ​DANCR              
is highly conserved between humans and mice with well-defined locations.​17, 23-24           
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Because ​DANCR is an intergenic lncRNA, we avoided results that may have been due              
to gene expression. For these reasons, we hypothesize that ​DANCR would be a good              
candidate to elucidate its role in LSCs. 
Long Term Culture - Initiating Cell (LTC-IC) Assay 
Murine fibroblasts were cultured to confluency of 80% before the cells were irradiated             
(80 Gy). CD34 + cells from AML patients were cultured in MyeloCult supplemented with              
hydrocortisone sodium succinate. Cells were treated with transferrin-NP-siDANCR or         
transferrin-NP-siSCR containing 300nM of siRNA for 24h in liquid culture prior to            
seeding the cells in two different concentrations on the feeding layers. The media for the               
assay was partially changed every week. After 6-weeks of culture, cells were harvested,             
and equal numbers of cells were seeded in Methocult where colonies were counted             
after 14 days and the frequency of stem cells was calculated according to the              
manufacturer’s recommendation (Figure 2). We confirmed that ​DANCR expression was          
significantly higher in the LSC enriched population. These results suggest that a high             
DANCR expression can be used to identifying the LSC-enriched population within an            
individual patient. 
Real Time PCR Expression Measurement 
DANCR expression in AML blasts was determined using qRT-PCR in AML patients            
compared to healthy donor BM. ​DANCR expression was variable between patients,           
however it was overall elevated significantly compared to healthy controls (Figure 3;            
p<0.01). 
DANCR​ Knockdown with Nanoparticle in Colony Forming Unit (CFU) Assay 
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Image 1​: Small interfering RNA (siRNA) against human DANCR in Nanoparticle. Briefly,            
positively charged polyethylenimine was used to capture negatively charged siRNAs,          
the complex was then loaded into pre-made NPs, which consist of           
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dimyristoyl-sn-glycerol,   
methoxypolyethylene glycol (DMG-PEG) and linoleic acid. Transferrin or anti-CD45.2         
antibody conjugated with   
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene 
glycol)-2000] (DSPEPEG2000 maleimide) was then inserted in the NP. 
 
CFU assays were performed by first treating primary CD34+ AML patients’ cells with             
transferrin-NP-siDANCR or transferrin-NP-siSCR containing 300 nM siRNA (Figure 4).         
After 24 hours of treatment, 2,000-50,000 cells/dish allowed to proliferate for 14 days             
and then scored for the number of colonies. Cells from primary colonies were then              
isolated for colony re-plating assays. MethoCult was dissolved in warm RPMI medium            
containing 20% FBS. Cells were spun, washed with RPMI medium, and counted. Cells             
were then seeded (10,000-50,000 cells/dish) onto at least duplicate plates without           
further treatment. Cells were cultured for additional 14 days and then scored. 
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Image 2: Blast cells were harvested after nanoparticle knockdown. Cells were plated            
and allowed to proliferate before they were recollected and replated without additional            
treatment. 
 
Using this nanoparticle ​DANCR knockdown method in primary AML blasts, we           
examined the impact of ​DANCR in LSC self-renewal using colony forming unit (CFU)             
replating assays. We found significantly fewer colonies in the secondary plating           
compared to scramble controls (Figure 5; n=3, p=0.03, average decrease~39%). Since           
LSCs are generating during secondary replating, this indicated a correlation between           
DANCR​ and LSC self-renewal capacity. 
Celltrace Violet - Quiescence Assessment 
 
Image 3:​ Quiescent cells. This image shows that cells that do not divide frequently are 
considered to be quiescent cells. These are also the most infrequent cell type. 
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Primary CD34 + AML patients’ cells (10 x 10​6​) were re-suspend in FBS enriched PBS. A                
CTV solution was added. Cell suspension was gently vortexed and incubated for 3             
minutes in the dark. The cell suspension was directly quenched with cold RPMI medium              
containing FBS and kept on ice for 5 minutes. Cells were then washed and              
resuspended in PBS with 2% FBS. Next, cells were sorted using an ARIA II cell sorter                
for CTV fluorescence. To get a baseline staining, some cells were stained with an              
anti-CD34 antibody labeled with PEcy7 and 7-AAD viability staining. Next, we           
demonstrated the differentiation of regularly proliferating cells and quiescent cells.          
Celltrace violet (CTV) dye was used to assess the effect of ​DANCR knockdown on AML               
blast quiescence. We found that primary AML blasts treated with Tf-NP-si​DANCR had a             
significant decrease in the number of quiescent (CTV max /CD34+) cells (p<0.05)            
compared to Tf-NP-siSCR controls. Figure 6 demonstrates our findings. 
Nanoparticle In-vivo Experiments 
 
Image 4: Primary AML BM cells are harvested and injected into radiation conditioned             
mice. These mice were treated with SCR or anti-Dancr before they were sacrificed and              
their BM was harvested for a secondary transplantation. 
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First, we transplanted leukemic cells (CD45.2+) into lethally irradiated wild-type          
(WT)-BoyJ (CD45.1+) mice with whole BM cells from healthy WT-BoyJ donors           
(CD45.1+). Two weeks after engraftment, mice were treated with NPs conjugated with            
an anti-CD45.2 antibody to target the leukemic cells.​6, 27 Mice were then treated for five               
consecutive days via intraperitoneal injection, and were sacrificed 48 hours after their            
final dosage. Their BM was harvested and sufficient ​Dancr knockdown was confirmed            
(p = 0.002). Next, we determined whether Dancr knock-down affected engraftment in            
secondary BM transplantation, a key feature of stem cells. Different concentrations (2 ×             
10​6​, 1 × 10​6​, 5 × 10​5 of viable cells/mouse) of leukemic donor cells from mice treated                 
with anti-CD45.2-NP-siDancr or anti-CD45.2-NP-siSCR were transplanted into lethally        
irradiated BoyJ recipients (n = 5 per concentration group). Two weeks after            
transplantation, we found significant decreases in engraftment in mice transplanted with           
cells from anti-CD45.2-NP-siDancr-treated mice at the two lower cell concentrations (5           
× 10​5​: p = 0.005; 1 × 10​6​: p = 0.037), however no significant decrease was found at the                   
highest concentration (2 × 10​6​: p = 0.50) compared with mice transplanted with cells              
from anti-CD45.2-NP-siSCR control-treated mice (Figure 6). We continued to observe          
these mice which revealed differences in overall survival, with mice transplanted with            
cells from anti-CD45.2-NP-siDancr primary donors having significantly longer survival         
than mice transplanted with cells from the anti-CD45.2-NP-siSCR-treated primary         
donors. This was found for all concentrations of leukemic donor cells, namely 2 × 10​6               
(median, 62 vs 41 days, p < 0.001), 1 × 10​6 (median, 76 vs 63 days, p < 0.001), and 5 ×                      
10​5 (Figure 8; median, 78 vs 69 days, p < 0.001). We calculated the LSC frequency                
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which showed that Dancr knock-down significantly decreased the number of LSCs per            
total number of cells (p < 0.001). 
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Section 4: Discussion 
Prognosis for AML patients is still poor, and failure to therapies and relapse after              
achievement of a complete remission present the major clinical challenges.​1,2,7 To           
improve patients’ outcome, attending to LSCs is necessary to eradicate the disease.​13            
Thus, a better understanding of LSC biology is necessary to develop novel therapies to              
target and eliminate the LSCs. We previously showed that LSCs have a distinct             
microRNA (miR) expression profile.​3,4,6,25 However, the role and significance of lncRNAs           
in LSCs is not fully understood.  
Using the CE-GES score published by Eppert et al.​4 which is based on expression of 44                
protein coding genes known to be deregulated in LSCs, we calculated the CE score in               
375 younger and 76 older adult CN-AML patients. CE-GES is driven by stem cell              
biology comparing gene expression signatures associated with LSCs and HSCs. Our           
analysis using generated a signature consisting of 111 lncRNAs that correlated with            
CE-GES​High​ in two different data sets of younger and older CN-AML patients.  
We further validated the significance of the CE-GES-associated lncRNA signature by           
demonstrating that one lncRNA, ​DANCR​, also plays a functional role in LSCs. We             
chose ​DANCR to further analyze because it has been shown to be involved in              
regulating the WNT pathway, which is critical for stem cell functions.​19 It has been              
shown to be a key regulator in the development stem-like HCC. We identified similar              
mechanistic results of ​DANCR in AML showing that a knockdown of ​DANCR led to a               
decrease in the WNT pathway indicating that the mechanism of action of ​DANCR in              
AML might be similar to that of HCC. It is highly conserved between mouse and               
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human.​23,24 Importantly, ​DANCR is an intergenic lncRNA, which avoids the possible           
confounding variable of being co-regulated with its host gene.  
Although further analyses are necessary to fully dissect the mechanistic role of DANCR             
in AML cells, especially in LSCs, we have demonstrated for the first time the functional               
role of DANCR in LSCs utilizing cells from AML patients and anti-​DANCR siRNA loaded              
transferrin- or antibody-conjugated NPs.​26,27 Our previous studies showed the efficiency          
of the NP to deliver antagomiRs to LSCs in AML patient-derived samples in             
xenotransplantation models.​6,26,27 This approach opens the possibility of the first          
lncRNA-based therapeutic approach for targeting the highly relevant LSC         
subpopulation.​6,26,27 Our data show that the transferrin/antibody-conjugated NPs result in          
sufficient knockdown of ​DANCR after only a few doses and without any observable             
toxicity. 
Furthermore, we demonstrate that ​DANCR knockdown had an impact on basic           
stem-cell features such as self-renewal and quiescence. We translated these data ​in            
vivo and found that in secondary transplants there was a delay of disease development              
and prolonged survival of leukemic mice. However, ​due to the experimental limitations            
as a result of not being able to isolate an immunophenotypically distinct LSC population,              
we cannot exclude the possibility that ​DANCR may be involved in other cell processes              
such as proliferation, survival, or metabolism, among others. 
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Section 5: Conclusion 
In conclusion, we identified an LSC-specific lncRNA signature in AML consisting of 111             
lncRNAs. We chose to functionally validate one of these lncRNAs and demonstrate that             
this lncRNA, ​DANCR​, regulates LSC self-renewal and quiescence. Our data conclude           
that ​DANCR was not only significantly higher expressed in AML cells compared to             
healthy BM cells but also higher expressed in the LSC enriched compartment within all              
analyzed patients. To determine ​DANCR function in LSCs, we used a           
transferrin-conjugated anionic lipopolyplex nanoparticle-based knockdown of ​DANCR to        
assess its on LSCs. We found ​DANCR regulated LSC self-renewal capacity using CFU             
replating assays. Furthermore, we found ​DANCR also regulates cellular quiescence          
using membrane labeling retention assays (CTV). Using nanoparticles containing         
siRNA-anti-​DANCR​, we demonstrated that ​DANCR can be targeted in vivo and           
represents a novel target in patients with AML. 
These data provide strong evidence that our LSC lncRNA signature may comprise            
functionally relevant lncRNAs regulating LSC biology and therefore may represent a list            
of novel LSC-specific therapeutic targets in AML. 
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Section 6: Impact Innovation 
A better understanding of AML pathogenesis and biology is crucial for the hopes of              
improving patient outcomes. Distinguishing the role of lncRNA in LSCs has the potential             
to identify novel targets for treating AML patient. For the first time, we have identified a                
role for the lncRNA, ​DANCR​, to regulate LSCs in AML. We have dissected ​DANCR​’s              
contribution to leukemogenesis by investigating the effects of ​DANCR knockdown on           
cell self-renewal and partial maturation abilities. Our goal is to one day use this              
knowledge to develop personalized novel therapies for each AML patient.          
Understanding the biology and mechanisms regulating LSCs will open the doors to            
personalized treatment. This would not only allow for better responses to initial            
therapies but could also prevent minimal residual disease and relapse. 
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Section 7: Supplemental Material 
 
Figure 1 - (A) Heat map of 365 younger (aged <60 years) adult patients with               
cytogenetically normal AML (CN-AML). Each column represents a single patient.          
Patients were classified according to their core enriched (CE) gene expression           
signature (GES). Patients on the left side had a lower CE-GES score while patients on               
the right side were CE​High​. Each row indicates a lncRNA that was significantly             
deregulated between CE​Low and CE​High patients; these lncRNAs were cross validated in            
a set of 76 older CN-AML patients. Expression values of the lncRNAs are represented              
by color, with red indicating higher expression and green indicating lower expression. 
 
 
 
 
Figure 2 – LTC-IC results of 3 AML patient. A knock-down of ​DANCR leads to a                
significant decrease in LSC frequency 
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Figure 3 - qRT-PCR of healthy bone marrow (n=3) and AML patients marrow (n=9).              
Although ​DANCR ​expression varied, it was significantly higher expressed in several           
patients with AML (P<0.05) 
 
Figure 4 - Target and knock-down of ​DANCR using loaded nanoparticle           
(NP-anti-​DANCR​) compared to a scramble control (NP-SCR). Transferrin was added to           
target LSCs. Data of CD34+ enriched AML patient cells (*P<0.05, **P<0.01) 
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Figure 5 - Colony forming units (CFUs) were performed by using NP-anti-​DANCR or             
scramble control (NP-SCR) treated cells plated in methylcellulose media. Cells were           
then replated to evaluate self-renewal capacity, a characteristic of LSC (*P<0.05,           
**P<0.01) 
 
Figure 6 ​- Quiescent cells are cells that rarely divide; a characteristic of LSCs Cell trace                
violet (CTV) proliferation assays were performed on AML blasts treated with           
NP-anti-​DANCR and NP-SCR with CTV dye and were cultured for three days.            
Quiescent CTVmax/CD34+ cells (*P<0.05, ****P<0.0001) 
 
Figure 7 - Three dose concentrations of harvested cells were administered to BoyJ             
mouse recipients (n=5 per group). Engraftment of treated mice were compared           
(***P<0.001). 
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Figure 8 - Three dose concentrations of harvested cells were administered to BoyJ             
mouse recipients (n=5 per group). Engraftment of treated mice were compared           
(***P<0.001). 
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